Moclobemide in the treatment of hot flashes in postmenopausal women

Advances in Therapy

Volumn 19, Issue 6, 2002, Pages 258-265

  Tarim, Ebru ^a   Bagis, Tayfun ^a,b   Kilicdag, Esra ^a   Erkanli, Serkan ^a   Aslan, Erdogan ^a   Kuscu, Esra ^a  

^a BASKENT UNIVERSITY   (Turkey)

^b Guzelyali Mah Adnan Kahveci Bul ^*  (Turkey)

Author keywords

Hot flashes; Menopause; Moclobemide; SSRIs

Indexed keywords

ESTROGEN; MOCLOBEMIDE; MONOAMINE OXIDASE A INHIBITOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HOT FLUSH; HUMAN; INCIDENCE; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0036881287     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02853171     Document Type: Article

References (31)

1. Bachman GA. Non hormonal alternatives for the management of early menopause in younger women with breast cancer. J Natl Cancer Inst Monogr. 1994;16:161-167.
2. Valagussa P, DeCandis D, Antonelli G, et al. Women's health perception and breast cancer: issues of fertility, hormone substitution, and cancer prevention. Recent Results Cancer Res. 1996;140:277-283.
3. Reyno LM, Levine MN, Skingley P, et al. Chemotherapy induced amenorrhea in a randomized trial of adjuvant chemotherapy duration in breast cancer. Eur J Cancer. 1992;29A:21-23.
4. Collchio F, Pandya K. Amenorrhea following chemotherapy for breast cancer: effect on disease free survival. Oncology. 1994;8:45-51.
5. Loprinzi CL, Peethambaram PP. Management of menopausal symptoms in breast cancer patients. Ann Med. 1995;27:653-656.
6. Couzi RJ, Helzlsouer KJ, Fettin JH. Prevalence of menopausal symptoms among women with a history of breast cancer and attitudes toward estrogen replacement therapy. J Clin Oncol. 1995;13:2737-2744.
7. Kronenberg F. Hot flashes: epidemiology and physiology. Ann NY Acad Sci. 1990;592:52-86.
8. Mulley G, Mitchell JRA. Menopausal flashing: does estrogen therapy make sense? Lancet. 1976; i:1397-1398.
9. Aksel S, Schomberg DW, Tyrey L, Hammond CB. Vasomotor symptoms, serum estrogens, and gonadotropin levels in surgical menopause. Am J Obstet Gynecol. 1976;126:165-169.
10. Kronenberg F. Hot flashes: phenomenology, quality of life, and search for treatment options. Exp Gerontol. 1994;29:319-336.
11. Erlik Y, Tataryn IV, Meldum DR, et al. Association of waking episodes with menopausal hot flashes. JAMA. 1981;245:1741-1744.
12. Pearlstein T, Rosen K, Stone AB. Mood disorders and menopause. Endocrinol Metab Clin. 1997;26:279-294.
13. Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol. 1996;14:1718-1729.
14. Barton DL, Loprinzi CL, Quella SK, et al. Prospective evaluation of vitamin E for hot flashes in breast cancer survivors. J Clin Oncol. 1998;16:495-500.
15. Groeneveld FPMJ, Bareman FP, Barensten R, et al. Relationship between attitude toward menopause, well-being and medical attention among women aged 45-60 years. Maturitas. 1993;17:77-88.
16. Knopf MT. Physical and psychologic distress associated with adjuvant chemotherapy in women with breast cancer. J Clin Oncol. 1986;4:678-684.
17. Neugarten BL, Kraines RJ. 'Menopausal symptoms' in women of various ages. Psychosom Med. 1965;27:266-273.
18. Halbreich U. Role of estrogen in postmenopausal depression. Neurology. 1997;48:S16-S19.
19. Sherwin BB. Hormones, mood, and cognitive functioning in menopausal women. Obstet Gynecol. 1996;87:20S-26S.
20. Stearns V, Isaacs C, Rowland J, Crawford J, Ellis MJ, Kramer R. A pilot trial assessing the efficacy of paroxetine hydrochloride in controlling hot flashes in breast cancer survivors. Ann Oncol. 2000;11:17-22.
21. Loprinzi C, Pisansky T, Fonseca R, Sloan J, Zahasky K. Pilot evaluation of venlafaxine hydrochloride for the therapy of hot flashes in cancer survivors. J Clin Oncol. 1998;16:2377-2381.
22. Volz HP, Gleiter CH. Monoamineoxidase inhibitors. A perspective on their use in the elderly. Drugs Aging. 1998;13:341-355.
23. Loprinzi CL, Michalak JC, Quella SK, et al. Megestrol acetate for the prevention of hot flushes. N Engl J Med. 1994;331:347-352.
24. McEwen BS. Clinical review 108: the molecular and neuroanatomical basis for estrogen effects in the central nervous system. J Clin Endocrinol Metab. 1999;84:1790-1797.
25. McEwen BS. Estrogen actions in the central nervous system. Endocrinol Rev. 1999;20:278-306.
26. Janowsky DS, Halbreich U, Rausch J. Association of ovarian hormones, other hormones, emotional disorders, and neurotransmitters. In: Jensvold MF, Halbreich U, Hamilton JA, eds. Psychopharmacology and Women: Sex, Gender, and Hormones. Washington, DC: American Psychiatric Press; 1996:85-104.
27. Schmidt PJ, Rubinow DR. Menopause related affective disorders: a justification for further study. Am J Psychiatry. 1991;148:844-852.
28. Klaiber EL, Kobayashi Y, Broverman DM, et al. Plasma monoamine oxidase activity in regularly menstruating women and in amenorrheic women receiving cyclic treatment with estrogens and progestins. J Clin Endocrinol Metab. 1971;33:630-638.
29. Gonzales GF, Carrillo C. Blood serotonin levels in postmenopausal women: effects of age and serum estradiol levels. Maturitas. 1993;17:23-29.
30. Fulton B, Benfield P. Moclobemide: an update of its pharmacological properties and therapeutic use. Drugs. 1996;52:450-474.
31. Goldberg RJ. Antidepressant use in the elderly. Current status of nefazodone, venlafaxine and moclobemide. Drugs Aging. 1997;11:119-131.